EA200200702A1 - Замещенные 8-арилхинолиновые ингибиторы фосфодиэстеразы-4 - Google Patents

Замещенные 8-арилхинолиновые ингибиторы фосфодиэстеразы-4

Info

Publication number
EA200200702A1
EA200200702A1 EA200200702A EA200200702A EA200200702A1 EA 200200702 A1 EA200200702 A1 EA 200200702A1 EA 200200702 A EA200200702 A EA 200200702A EA 200200702 A EA200200702 A EA 200200702A EA 200200702 A1 EA200200702 A1 EA 200200702A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alkyl
aryl
alkoxy
heteroaryl
halogen
Prior art date
Application number
EA200200702A
Other languages
English (en)
Other versions
EA004747B1 (ru
Inventor
Дени Дешен
Дэниел Дюб
Мишель Галлан
Ив Жирар
Патрик Лякомб
Дуайт Макдональд
Энтони Мастраччо
Элен Перье
Original Assignee
Мерк Фросст Кэнада Энд Ко.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Фросст Кэнада Энд Ко. filed Critical Мерк Фросст Кэнада Энд Ко.
Publication of EA200200702A1 publication Critical patent/EA200200702A1/ru
Publication of EA004747B1 publication Critical patent/EA004747B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Новые замещенные 8-арилхинолины, представленные формулой (I), или их фармацевтически приемлемые соли, где S, Sи Sнезависимо представляют Н, -ОН, галоген, -C-C-алкил, -NO, -CN или -C-C-алкокси, где алкильная и алкоксигруппы необязательно замещены 1-5 заместителями; где каждый заместитель независимо представляет собой галоген или ОН; Rпредставляет собой Н, ОН, галоген, карбонильную или -C-C-алкильную, -цикло-C-C-алкильную, -C-C-алкенил,-C-C-алкокси, арильную, гетероарильную, -CN, -гетероцикло-C-C-алкильную, -амино, -C-C-алкиламино, -(C-C-алкил)(C-C-алкил)амино, -C-C-алкил(окси)C-C-алкильную, C(O)NH(арил), -С(О)NH(гетероарил), -SONH(арил), -SONH-(гетероарил), -SONH(C-C-алкил), -С(О)N(C-C-алкил) (C-C-алкил), -NH-SO-(C-C-алкил), -SO-(C-C-алкил), -(C-C-алкил)-O-С(CN)-диалкиламино или -(C-C-алкил)-SO-(C-C-алкил) группу, где любая из групп необязательно замещена 1-5 заместителями; где каждый заместитель независимо представляет собой галоген, -ОН, -CN, -C-C-алкил, -цикло-C-C-алкил, -С(О)(гетероцикло-C-C-алкил), -С(О)-О-(C-C-алкил), -С(О)-арилокси, -C--C-алкокси, -(C-C-алкил)(C-C-алкил)амино, циклоалкилокси, ацил, ацилокси, -цикло-C-C-алкил, гетероцикло-C-C-алкил, арил, гетероарил, карбонил, карбамоил или -SO-(C-C-алкил); А представляет собой СН, С-сложный эфир или C-R; Rи Rнезависимо представляют арильную, гетероарильную группу, Н, галоген, -CN, -C-C-алкильную, гетероцикло-Салкильную, -C-C-алкокси, карбонильную, карбамоильную, -С(О)ОН, -(C-C-алкил)-SO-(C-C-алкил), -С(О)N(C-C-алкил) (C-C-алкил) или -C-C-алкилациламино группу, где любая из групп необязательно замещена 1-5 заместителями, где каждый заместитель независимо представляет собой заместитель арил, гетероарил, галоген, -NO, -С(O)ОН, карбонил, -CN, -C-C-алкил, -SO-(C-C-алкил), -SO-(арил), арилокси, -гетероарилокси, C-C-алкокси, N-оксид, -С(О)-гетероцикло-C-C-алкил, -NH-цикло-C-C-алкил, амино, -ОН или -(C-C-алкил) (C-C-алкил)амино, -С(О)-N(C-C-алкил)(C-C-алкил), где каждый заместитель независимо необязательно замещен -ОН, C-C-алкокси, -C-C-алкилом, -цикло-C-C-алкилом,
EA200200702A 1999-12-22 2000-12-20 Замещенные 8-арилхинолиновые ингибиторы фосфодиэстеразы-4 EA004747B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17152299P 1999-12-22 1999-12-22
PCT/CA2000/001559 WO2001046151A1 (en) 1999-12-22 2000-12-20 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors

Publications (2)

Publication Number Publication Date
EA200200702A1 true EA200200702A1 (ru) 2003-02-27
EA004747B1 EA004747B1 (ru) 2004-08-26

Family

ID=22624050

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200702A EA004747B1 (ru) 1999-12-22 2000-12-20 Замещенные 8-арилхинолиновые ингибиторы фосфодиэстеразы-4

Country Status (32)

Country Link
EP (1) EP1244628A1 (ru)
JP (1) JP3782011B2 (ru)
KR (1) KR20020082839A (ru)
CN (1) CN1221534C (ru)
AR (1) AR029214A1 (ru)
AU (1) AU778531B2 (ru)
BG (1) BG65403B1 (ru)
BR (1) BR0016651A (ru)
CA (1) CA2393749C (ru)
CO (1) CO5261613A1 (ru)
CZ (1) CZ20022171A3 (ru)
DZ (1) DZ3244A1 (ru)
EA (1) EA004747B1 (ru)
EE (1) EE200200342A (ru)
GE (1) GEP20053626B (ru)
HK (1) HK1057560A1 (ru)
HR (1) HRP20020545A2 (ru)
HU (1) HUP0203896A3 (ru)
IL (1) IL150114A0 (ru)
IS (1) IS6413A (ru)
MX (1) MXPA02006329A (ru)
MY (1) MY134008A (ru)
NO (1) NO20023013L (ru)
NZ (1) NZ520258A (ru)
PE (1) PE20010989A1 (ru)
PL (1) PL355752A1 (ru)
SK (1) SK8972002A3 (ru)
TW (1) TWI280240B (ru)
UA (1) UA74815C2 (ru)
WO (1) WO2001046151A1 (ru)
YU (1) YU47102A (ru)
ZA (1) ZA200204862B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10110772A1 (de) * 2001-03-07 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
CN1211383C (zh) * 2000-12-20 2005-07-20 麦克公司 制备取代的8－芳基喹啉鎓苯磺酸盐的方法
US6740666B2 (en) * 2000-12-20 2004-05-25 Merck & Co., Inc. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
DE60204463T2 (de) * 2001-06-27 2006-05-18 Merck Frosst Canada & Co, Kirkland Substituierte 8-Arylchinoline als PDE4-Hemmer
US7009055B2 (en) * 2001-07-24 2006-03-07 Merck & Co., Inc. Preparation of Sulfonyl quinoline
ATE349243T1 (de) * 2001-09-19 2007-01-15 Altana Pharma Ag Kombination von einem pde-hemmer und eines leukotrien rezeptor antagonisten
ATE432261T1 (de) * 2002-03-18 2009-06-15 Merck Frosst Canada Ltd Pde4-inhibitoren mit heterobrückensubstituiertem 8-arylchinolin
BRPI0408005A (pt) * 2003-03-05 2006-02-14 Celgene Corp composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor
AU2005226741A1 (en) * 2004-03-25 2005-10-06 Synta Pharmaceuticals Corp. Acrylonitrile derivatives for inflammation and immune-related uses
WO2006123954A1 (en) * 2005-05-19 2006-11-23 Synergenz Bioscience Limited Methods and compositions for assessment of pulmonary function and disorders
PL2363130T3 (pl) 2006-07-05 2014-09-30 Astrazeneca Ab Kombinacja inhibitorów reduktazy HMG-CoA atorwastatyny i symwastatyny z inhibitorem fosfodiesterazy, takim jak roflumilast do leczenia zapalnych chorób płuc
US7745646B2 (en) * 2006-07-07 2010-06-29 Kalypsys, Inc. Bicyclic heteroaryl inhibitors of PDE4
AU2007299726A1 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2011099305A1 (en) 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
AU2018326785B2 (en) 2017-09-03 2023-03-02 Angion Biomedica Corp. Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
US6245774B1 (en) * 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
JPH11209350A (ja) * 1998-01-26 1999-08-03 Eisai Co Ltd 含窒素複素環誘導体およびその医薬

Also Published As

Publication number Publication date
ZA200204862B (en) 2003-03-17
DZ3244A1 (fr) 2001-06-28
EA004747B1 (ru) 2004-08-26
HUP0203896A2 (hu) 2003-04-28
NO20023013D0 (no) 2002-06-21
CN1434801A (zh) 2003-08-06
AR029214A1 (es) 2003-06-18
BG106840A (en) 2003-01-31
YU47102A (sh) 2005-06-10
EP1244628A1 (en) 2002-10-02
TWI280240B (en) 2007-05-01
GEP20053626B (en) 2005-10-10
CO5261613A1 (es) 2003-03-31
PE20010989A1 (es) 2001-10-01
CA2393749A1 (en) 2001-06-28
NZ520258A (en) 2004-05-28
JP2003531112A (ja) 2003-10-21
AU778531B2 (en) 2004-12-09
MXPA02006329A (es) 2004-05-14
CA2393749C (en) 2008-06-17
HUP0203896A3 (en) 2003-05-28
JP3782011B2 (ja) 2006-06-07
CZ20022171A3 (cs) 2002-11-13
MY134008A (en) 2007-11-30
PL355752A1 (en) 2004-05-17
BR0016651A (pt) 2002-09-10
AU2336201A (en) 2001-07-03
WO2001046151A1 (en) 2001-06-28
IS6413A (is) 2002-06-11
IL150114A0 (en) 2002-12-01
UA74815C2 (en) 2006-02-15
BG65403B1 (bg) 2008-06-30
HK1057560A1 (en) 2004-04-08
NO20023013L (no) 2002-08-22
CN1221534C (zh) 2005-10-05
SK8972002A3 (en) 2002-11-06
EE200200342A (et) 2003-06-16
KR20020082839A (ko) 2002-10-31
HRP20020545A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
EA200200702A1 (ru) Замещенные 8-арилхинолиновые ингибиторы фосфодиэстеразы-4
RS49921B (sr) Terapeutski biaril derivati
EA200300763A1 (ru) Пиридиновые ингибиторы матриксных металлопротеиназ
HRP20020307B1 (en) Novel derivatives of dicarboxylic acid having pharmaceutical properties
RU2001121138A (ru) Ингибиторы тромбина
CO5251464A1 (es) Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina
RS51681B (sr) Piperazinil i diazapanil benzamidi i benztioamidi
ATE20064T1 (de) Anti-ischaemische und antihypertensive dihydropyridin-derivate.
SE0101579D0 (sv) New compounds
NO20024906D0 (no) Antitumorale ekteinascidinderivater
DE69810958D1 (de) Harnstoffderivate und ihre anwendung als integrin-inhibitoren
KR920006322A (ko) 벤젠, 피리딘 및 피리미딘 유도체
KR970703324A (ko) 신규한 피리미딘 유도체(novel pyrimidine derivative)
BG97221A (bg) Ортозаместени бифениламидини и бифенилизанидини и съдържащите ги антидиабетични или хипогликемични средства
KR910007883A (ko) 퀴놀린 유도체, 그의 제조방법 및 용도
NO944069L (no) Hemming av uterinfibrose
NZ337766A (en) Process for preparing pesticidal pyrazole derivatives
IE44765L (en) N-substituted benzamides.
NZ332030A (en) Sulfonamide substituted chromans, processes for their preparation, their use as a medicament and pharmaceutical preparations comprising them
EP0377966A3 (en) Novel benzopyranylpyrrolinone derivatives
ZA979328B (en) Process for the preparation of n-[2-(dimethylamino)ethyl[acridine-4-carboxamide
ATE118207T1 (de) Heterozyklische acylaminodiol-beta-aminosäure- derivate.
MY123639A (en) Substituted isoquinoline derivatives and their use as inticonvulsants
IE790013L (en) Polysubstituted-2-(3-loweralkylamino-2-or(1)-propoxy)¹pyridines
GB1397060A (en) 1,4-dighiino 2,3-c pyrrole derivatives

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU